Andrew joined SV in 2022 as an Associate on the Healthcare Growth Team.
Prior to joining SV, Andrew was a member of Thermo Fisher Scientific’s Corporate Development team, focused on mergers and acquisitions of healthcare and life science companies. He executed two M&A transactions with an aggregate value of $550 million.
Outside of SV, Andrew enjoys exploring Boston, golfing, skiing, and spending time with family and friends.
B.S., Business Administration: Finance, University of New Hampshire